Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety study of tafamidis in transthyretin cardiomyopathy (ATTR-CM)
jRCT2080223517Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2017
- Modality
- Small Molecules
01
Overview
Phase 3, open-label trial of tafamidis in amyloidotic transthyretin cardiomyopathy (ATTR-CM) (2 cohorts), sponsored by Pfizer. Primary endpoint: Long-term safety of tafamidis. Started Apr 2017; status: completed.
02
Drugs
tafamidis
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on jRCT2080223517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223517.